Business Context and Reporting Period
This Form 8-K, filed on January 5, 2021, reports events occurring on December 31, 2020, for Landec Corporation (ticker: LNDC). The filing details the entry into new material definitive credit agreements by Landec Corporation and its subsidiaries, Curation Foods, Inc. and Lifecore Biomedical, Inc., to refinance existing debt obligations.
Key Financial Metrics and Debt Structure
The filing establishes a new capital structure consisting of a Term Loan and a Revolver, replacing the prior credit agreement dated September 23, 2016.
- Term Loan Facility: Total capacity of $170.0 million.
- Initial tranche: $150.0 million funded at closing.
- Delayed draw tranche: $20.0 million available until December 31, 2022, subject to leverage ratios.
- Maturity: December 31, 2025.
- Interest Rate: LIBOR + 850 bps (floor 100 bps) or Base Rate + 750 bps (floor 300 bps).
- Revolver Facility: Capacity up to $75.0 million (subject to borrowing base calculations and reserves).
- Borrowing Base: Calculated based on percentages of eligible accounts receivable (85-90%), inventory (75-85%), and in-transit inventory (70-85%).
- Maturity: December 31, 2025 (or October 2, 2025 if Term Loan remains outstanding).
- Interest Rate: LIBOR + 200-250 bps (floor 50 bps) or Base Rate + 100-150 bps (floor 150 bps), based on availability.
- Collateral: First priority security interests granted on equipment, real property, intellectual property, inventory, cash, and deposit accounts.
Material Changes Versus Prior Period
The primary material change is the full refinancing of the Company's existing credit agreement with JPMorgan Chase Bank, N.A., BMO, and City National Bank. The new agreements introduce specific financial covenants not detailed in the prior arrangement within this filing, including:
- Fixed Charge Coverage Ratio: Minimum of 1.10 to 1.00 (commencing May 30, 2021), increasing to 1.40 to 1.00 by August 31, 2024.
- Leverage Ratio: Maximum of 7.00 to 1.00 (commencing February 28, 2021), decreasing to 4.00 to 1.00 by February 28, 2025.
- Lifecore Gross Profits: Minimum covenant starting at $28.75 million (February 28, 2021), increasing to $40.0 million by November 30, 2023.
- Liquidity: Minimum liquidity covenant of $7.5 million (defined as revolver availability plus qualified cash).
Guidance, Risks, and Contingencies
The filing does not provide forward-looking revenue or earnings guidance. However, it outlines significant risks and contingencies associated with the new debt:
- Covenant Compliance: The Company must adhere to strict financial covenants, including a specific gross profit target for the Lifecore subsidiary. Failure to meet these could trigger a default.
- Events of Default: Includes failure to pay, covenant breaches, bankruptcy, material inaccuracies in representations, and specific regulatory actions by the FDA.
- Change of Control: A change of control of the Company is listed as an event of default.
- Springing Covenants: The Revolver includes a springing fixed-charge coverage ratio of 1.0 to 1.0 if borrowing availability falls below $7.5 million or 10% of the Maximum Borrowing Amount.
Investor Verification Checklist
- Verify the actual drawdown amount of the $20.0 million delayed term loan tranche and the conditions required to access it.
- Confirm the current borrowing base availability under the Revolver, as it is subject to fluctuating asset values (receivables and inventory).
- Monitor Lifecore Biomedical's gross profit performance against the covenant minimums ($28.75 million starting Feb 2021).
- Review the impact of the new interest rate floors (100 bps for Term Loan, 50 bps for Revolver) on interest expense in a low-rate environment.
- Assess the Company's ability to maintain the minimum liquidity covenant of $7.5 million.